

Supplementary Table 6. DDI with DAA regimen by age group in HCV diagnosed patients

Age group	Total	LDV/SOF	SOF/VEL	GLE/PIB	<i>p</i> value
Contraindication					
18–34 years	80	35 (0.1)	13 (0.0)	32 (0.1)	0.0048
35–44 years	431	186 (0.4)	42 (0.1)	203 (0.4)	< 0.0001
45–54 years	2,476	1,088 (2.2)	197 (0.4)	1,191 (2.4)	< 0.0001
55–64 years	4,981	2,142 (4.3)	346 (0.7)	2,493 (5.0)	< 0.0001
65–74 years	4,432	1,863 (3.7)	254 (0.5)	2,315 (4.6)	< 0.0001
≥ 75 years	3,006	1,198 (2.4)	266 (0.5)	1,542 (3.1)	< 0.0001
Potential					
18–34 years	2,737	880 (1.8)	877 (1.8)	980 (2.0)	0.0216
35–44 years	7,609	2,457 (4.9)	2,536 (5.1)	2,616 (5.2)	0.0724
45–54 years	25,628	8,224 (16.5)	8,878 (17.8)	8,526 (17.1)	< 0.0001
55–64 years	35,939	11,523 (23.1)	12,907 (25.9)	11,509 (23.1)	< 0.0001
65–74 years	26,876	8,624 (17.3)	9,909 (19.9)	8,343 (16.7)	< 0.0001
≥ 75 years	17,536	5,721 (11.5)	6,381 (12.8)	5,434 (10.9)	< 0.0001

Values are presented as number (%).

% of DDIs were rounded to 1 decimal place.

The proportion shows the number of patients taking DAA regimen with contraindication among HCV diagnosed patients.

DDI, drug-drug interaction; DAA, direct-acting antiviral; HCV, hepatitis C virus; LDV, ledipasvir; SOF, sofosbuvir; VEL, velpatasvir; GLE, glecaprevir; PIB, pibrentasvir.